After promising results from Reata's Phase 2a study of bardoxolone methyl in diabetic nephropathy, the Phase 2b study will look to confirm previous findings in a larger population with more severe kidney damage. This study will look at the effects of bardoxolone methyl in patients with type 2 diabeties mellitus and chronic kidney disease on eGFR and other perameters of kidney function. Patients will be randomized to one of three doses of bardoxolone methyl or placebo and followed for one year.

 

This study is currently ongoing, but not recruiting participants.

 

This is an open-label, randomized, dose-ranging trial to determine the effects of bardoxolone methyl (RTA 402) administered orally at three dose strengths on the glomerular filtration rate (as estimated by the MDRD formula) in patients with diabetic nephropathy. Patients in the current cohort received bardoxolone for 56 days.